Targeting PI3 kinase in cancer
- 1 February 2015
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 146, 53-60
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Cell-to-Cell Variability in PI3K Protein Level Regulates PI3K-AKT Pathway Activity in Cell PopulationsCurrent Biology, 2011
- Activating Mutations in TOR Are in Similar Structures As Oncogenic Mutations in PI3KCα2009
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- Class I PI3K in oncogenic cellular transformationOncogene, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994